Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Newsletter CORDIS Newsletter
Contenido archivado el 2024-05-29

Targeted delivery of nanomedicine

Objetivo

MEDITRANS will develop systems for targeted delivery of nanomedicines, which will be broadly applicable to disease. The focus is on chronic inflammatory disorders and cancer. Such industrially developed targeted products will improve therapy and in vivo visualisation of drug delivery/release processes.

Nanocarriers (nanoparticles, nanotubes, fullerenes), endowed with high targeting capabilities, will be designed in parallel with MRI probes that report on localisation of the targeted nanoparticulates, specific bio-markers, and the drug release process (MRI-guided drug delivery).

For reproducible behaviour in vivo, these nanomedicines containing drug payloads (e.g. pDNA, siRNA, small molecular weight agents) will have their physicochemical/stability properties characterised. 'Smart' delivery systems, tested in vitro, able to recognise the target, and to cross-relevant biological barriers, will be investigated for their responsiveness to the microenvironment of the target site (e.g. local pH).

Control of drug re lease, triggered by external physical means (e.g. temperature, light, magnetism, ultrasound) or by local stimuli within the pathological site (e.g. pH, enzymatic activity) will be investigated in vitro. Ways to direct the intracellular trafficking of nanocarriers, to achieve improved interaction with the intracellular target location, will be investigated.

In vivo applicability will be evaluated in clinically relevant models of disease. Toxicology aspects, industrial scale-up feasibility, long term stability, and feasibility to prepare clinical grade material will be covered.

Dissemination, training and exploitation will be done. MEDITRANS, duration 4 years, is a timely, interdisciplinary IP at the forefront of targeted nanomedicine, with a budget of 16.1M Euro, a grant of 11M Euro (68%), and 1581.75 person-months effort.

The 30 partners (12 European countries) are from industry (8), SMEs (5), universities (11), and research institutes (6).

Ámbito científico (EuroSciVoc)

Programa(s)

Tema(s)

Convocatoria de propuestas

FP6-2004-NMP-NI-4
Consulte otros proyectos de esta convocatoria

Régimen de financiación

IP - Integrated Project

Coordinador

UNIVERSITEIT UTRECHT
Aportación de la UE
Sin datos
Dirección
HEIDELBERGLAAN 8
80125 UTRECHT
Países Bajos
Enlaces
Coste total
Sin datos

Participantes (32)

Descargar Descargar el contenido de la página

Última actualización: 6 Septiembre 2024

Permalink: https://cordis.europa.eu/project/id/26668/es

European Union, 2026